首页> 外文OA文献 >Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin

【2h】

Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin

机译：II期开放标签，临床局部前列腺癌和高级销患者中中间端点生物标志物调节的多中心临床试验。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Jason Gee; Howard Bailey; KyungMann Kim; Jill Kolesar; Tom Havighurst; Kendra D. Tutsch; William See; Michael B. Cohen; Nick Street; Leon LeVan; David Jarrard; George Wilding;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin [J] . GeeJ., BaileyH., KimK., The Prostate . 2013,第9期

机译：II期开放标签，多中心临床试验，通过1α-羟基维生素D2调节临床上局限性前列腺癌和高级别别针患者的中间终点生物标志物
2. Phase II, multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): rationale and design of the ESMMO trial [J] . Nut Koonrungsesomboon, Nuttapong Ngamphaiboon, Natavudh Townamchai, BMC Cancer . 2020,第1期

机译：II期，多中心，开放标签，单臂临床试验评估霉酚酸酯Mofetil在高级局部晚期或转移性骨肉瘤（ESMMO）患者中的疗效和安全性：理论和设计的ESMMO试验
3. Phase II, Randomized, Placebo-Controlled Trial of Neoadjuvant Celecoxib in Men With Clinically Localized Prostate Cancer: Evaluation of Drug-Specific Biomarkers [J] . Emmanuel S. Antonamkis, Elisabeth I. Heath, Janet R. Walczak Journal of Clinical Oncology . 2009,第30期

机译：临床辅助前列腺癌男性新辅助塞来昔布治疗的II期随机安慰剂对照试验：药物特异性生物标志物的评估
4. DO CANCER CLINICAL TRIAL POPULATIONS TRULY REPRESENT CANCER PATIENTS? A COMPARISON OF OPEN CLINICAL TRIALS TO THE CANCER GENOME ATLAS [C] . NOPHARGEIFMAN, ATUL J.BUTTE Pacific Symposium on Biocomputing . 2016

机译：癌症临床试验群体真正代表癌症患者吗？对癌症基因组阿特拉斯公开临床试验的比较
5. Clinical predictive value of pre-clinical cancer models: A study of the predictive value of the in vitro cell line, human xenograft and murine allograft pre-clinical cancer models for phase II clinical trials of cytotoxic cancer drugs [D] . Voskoglou-Nomikos, Theodora 2001

机译：临床前癌症模型的临床预测价值：体外细胞系，人异种移植和小鼠同种异体移植临床前癌症模型对细胞毒性癌症药物II期临床试验的预测价值研究
6. Phase II Open Label Multi-Center Clinical Trial of Modulation of Intermediate Endpoint Biomarkers by 1α-Hydroxyvitamin D2 in Patients With Clinically Localized Prostate Cancer and High Grade Pin [O] . Jason Gee, Howard Bailey, KyungMann Kim, -1

机译：II期开放标签临床局部前列腺癌和高级销患者中中间端点生物标志物调节的多中心临床试验。
7. Phase II, Randomized, Placebo-Controlled Trial of Neoadjuvant Celecoxib in Men With Clinically Localized Prostate Cancer: Evaluation of Drug-Specific Biomarkers [O] . Antonarakis, Emmanuel S., Heath, Elisabeth I., Walczak, Janet R., 2009

机译：新辅助塞来昔布治疗临床局部前列腺癌的男性的第二阶段随机安慰剂对照试验：药物特异性生物标志物的评估

Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin

著录项

引文网络

相似文献

相关主题

期刊订阅